Ergebnis der Suchanfrage nach R&amp

Orte

Damp Rampe

Inhalte

Neueste Relevanteste

15.11.2007 – 07:46
Finanzen
OMV Aktiengesellschaft
euro adhoc: OMV Aktiengesellschaft / quarterly or semiannual financial statement / Report January - September and Q3 2007 including interim financial statements as of September 30, 2007: Record result in Q3/07 with strong growth in all businesses
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 9-month report/OMV/Oil/Gas/Austria 15.11.2007 - Clean net income after minorities of EUR 489 mn, up 22% against Q3/06; strong contribution from Borealis and Petrol Ofisi and lower effective ...
mehr
29.10.2007 – 07:58
Finanzen
Palfinger Holding AG
euro adhoc: Mergers - Acquisitions - Takeovers / PALFINGER - Acquisition of MBB Liftsystems AG
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information/Übernahme 29.10.2007 Adhoc - R E L E A S E PALFINGER takes over one of the global leaders in tail lift manufacturing o 100 percent acquisition of MBB Liftsystems AG o Considerable strengthening of the TAIL LIFT product ...
mehr
25.10.2007 – 14:09
Wirtschaft
Boehringer Ingelheim
New Three-Year Data Confirms Aptivus(R) (tipranavir) as Effective and Durable Treatment Option for Treatment-Experienced Patients
Madrid, Spain (ots/PRNewswire) - - For Non-U.S. Media New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment- experienced HIV patients versus ...
mehr
06.09.2007 – 09:05
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim to Initiate First Phase III Pivotal Study for New Oncology Compound BIBW 2992(i)
Ingelheim, Germany (ots/PRNewswire) - - New Data on BIBW 2992(i), a Potent, Irreversible, Second-Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non-US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III ...
mehr
03.09.2007 – 10:04
Wirtschaft
Boehringer Ingelheim
Suffering in Silence - The Real Impact of the Last Taboo
Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...
mehr
25.07.2007 – 03:03
Finanzen
Boehringer Ingelheim
Data Presented at International AIDS Society (IAS) Conference Shows Long-Term Viramune(R) (nevirapine) Efficacy and Increase in Good Cholesterol
Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...
mehr

24.07.2007 – 08:05
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Announces First International Head-to-Head Trial of Aptivus(R) (tipranavir) versus darunavir in Treatment-Experienced HIV-Positive Patients
Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...
mehr
23.07.2007 – 03:45
Wirtschaft
Boehringer Ingelheim
International Experts and Women Living With HIV Discuss Urgent Needs of HIV-Positive Women at International AIDS Society (IAS) Congress
Sydney, Australia (ots/PRNewswire) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb-Ecf4-4d9f-9118-F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the ...
mehr
18.06.2007 – 10:05
Wirtschaft
Boehringer Ingelheim
New Study Shows That telmisartan has Greater Renoprotective Potential Than losartan in Hypertensive Patients With Type 2 Diabetes
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from ...
mehr
18.06.2007 – 10:03
Wirtschaft
Boehringer Ingelheim
More Than Half of Hypertensive Patients Remain Uncontrolled and at Higher Risk of Heart Attack and Stroke - Telmisartan May Decrease This Risk
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media - Results From Two Large, Multinational, Practice-Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension (ESH) show that measuring blood pressure in a doctor's office alone does ...
mehr
14.06.2007 – 14:11
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) in Diverse Group of Highly Treatment-Experienced HIV-Positive Patients
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-1 infected patients. The trial ...
mehr
14.06.2007 – 09:27
Finanzen
Curasan AG
curasan AG: REVOIS® All-in-One Dental Implant System Registered in the U.S.
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. new product Kleinostheim (euro adhoc) - curasan AG, a German leader in regenerative medicine, has obtained FDA clearance for its REVOIS® All-in-One dental implant system, permitting the sale of the system in the U.S. This means that the system can be ...
mehr

07.06.2007 – 18:20
Wirtschaft
Boehringer Ingelheim
Efficacy of Boehringer Ingelheim's Pramipexole (Mirapexin(R)/Sifrol(R) Also Demonstrated in Patients With Daytime RLS Symptoms
Ingelheim Am Rhein, Germany (ots/PRNewswire) - - Studies Reinforce the Benefits of Pramipexole From Daytime Symptom Control, Including Afternoon and Early Evening Onset - For Healthcare Media Outside the U.S.A. New data demonstrate that pramipexole (Mirapexin(R)/Sifrol(R)) is also efficacious and ...
mehr
10.05.2007 – 07:04
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS Trial
Ingelheim, Germany (ots/PRNewswire) - - Trial to Compare Efficacy and Safety of Viramune(R) (Nevirapine) Versus Atazanavir/Ritonavir in Treatment-Naive Patients Boehringer Ingelheim GmbH announced today that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune(R) (nevirapine), ...
mehr
22.03.2007 – 07:52
Finanzen
Wacker Chemie AG
WACKER had its best year ever in 2006
- Net income more than doubled to 311 million (2005: 144m) - Dividend of 2.00 per share proposed, plus a special bonus of 0.50 - Sales grew 21 percent to 3.34 billion (2005: 2.76bn) - In 2007 focus on capacity expansion and continued growth in sales and earnings ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. balance Munich (euro adhoc) - ...
mehr
19.03.2007 – 09:37
Finanzen
TUI AG
euro adhoc: TUI AG / Mergers - Acquisitions - Takeovers / Merger of TUI AG tourism division and First Choice Holidays PLC to create one of the worlds leading travel groups
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 19.03.2007 Hanover, 19 March 2007. The Boards of TUI AG and First Choice Holidays PLC ("First Choice") have today agreed to merge the tourism division of TUI AG exclud-ing ...
mehr
26.02.2007 – 18:09
Finanzen
Palfinger Holding AG
euro adhoc: Palfinger AG / Strategic management decisions / PALFINGER AG proposes share split
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information/share split 26.02.2007 PALFINGER Proposes Share Split Bergheim / Salzburg, February 26th, 2007 PALFINGER, the world market leader for truck-mounted knuckle-boom cranes, is proposing a 1:4 stock split for approval at its ...
mehr
31.01.2007 – 09:10
Wirtschaft
Boehringer Ingelheim
Data Published in AIDS Show Viramune(R) (nevirapine) Achieves Durable Benefit in Switch Patients
Ingelheim, Germany (ots/PRNewswire) - Long-term data from the Nevirapine/Efavirenz/Abacavir (NEFA) study demonstrate that patients who switched from a protease inhibitor-based regimen to a non-nucleoside reverse transcriptase inhibitor-based regimen containing Viramune(R) (nevirapine) or efavirenz achieved comparable efficacy and safety to their previous regimen ...
mehr

13.12.2006 – 07:59
Finanzen
Salzgitter AG
Salzgitter AG and Vallourec sign preliminary agreement regarding a possible acquisition of Vallourec's precision tubes activities
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Salzgitter (euro adhoc) - Salzgitter AG, Salzgitter and Vallourec SA, Paris, signed a preliminary agreement regarding the intended acquisition of Vallourec Précision Etirage (VPE), France, a ...
mehr
15.11.2006 – 08:05
Wirtschaft
Boehringer Ingelheim
Long-Term Data Show Aptivus(R) (tipranavir) Continues to Outperform Group of Protease Inhibitors in RESIST Trials
Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...
mehr
10.11.2006 – 14:59
Wirtschaft
Boehringer Ingelheim
FDA Approves Boehringer Ingelheim's Pramipexole for the Treatment of Moderate-to-Severe Primary Restless Legs Syndrome (RLS)
Ingelheim, Germany, November 10 (ots/PRNewswire) - - Millions of People Worldwide Living With RLS to Benefit as Treatment Becomes Globally Available Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the ...
mehr
07.11.2006 – 08:24
Finanzen
ElringKlinger AG
euro adhoc: ElringKlinger AG / Financial Figures/Balance Sheet / ElringKlinger with Double-digit Revenue and Earnings Growth after First Nine Months of 2006
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 07.11.2006 > Consolidated net income after minorities grows by 22% > Operating result up by 20% > Net cash from operating activities increases by 29% > Order intake improves by 16% year on ...
mehr
31.10.2006 – 08:32
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim's Pramipexole (Mirapexin(R)/Sifrol(R)) Shown to Improve Depressive and Motivational Symptoms in Parkinson's Disease
Kyoto, Japan (ots/PRNewswire) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease-Modification Trial - For non-US Healthcare Media New data presented today from a meta-analysis* of nearly 1,300 Parkinson's disease (PD) patients indicate that pramipexole (Mirapexin(R) ...
mehr
25.10.2006 – 12:17
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim: Unfounded Fear of Addiction Prevents Laxative Use
Berlin, Germany (ots/PRNewswire) - - Global Survey Highlights Misunderstandings About Causes and Treatment of Constipation - Not for use or publication in the USA Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show ...
mehr

05.09.2006 – 08:00
Panorama
Boehringer Ingelheim
Boehringer Ingelheim's pramipexole (Sifrol(R)/Mirapexin(R)) Can Provide Benefit of Improved Mood Disturbance for People With Restless Legs Syndrome
GLASGOW, Scotland (ots) - - FOR HEALTHCARE JOURNALISTS (For media outside the US only) - New Data Shows pramipexole is an Effective Treatment Option for the Broad Range of RLS Symptoms During Both the Night and Daytime New data indicate that when treated with ...
mehr
14.08.2006 – 17:04
Wirtschaft
Boehringer Ingelheim
Tipranavir Achieves Virologic and Immunologic Improvements in HIV-Positive Children at 48-Weeks of Therapy
Toronto (ots/PRNewswire) - New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV-1 infected children aged 2 to 18 years were announced today at the 16th International AIDS Conference (IAC) in Toronto, Canada. Results from this 48-week analysis show that patients achieved virologic ...
mehr
10.08.2006 – 08:07
Finanzen
ElringKlinger AG
euro adhoc: ElringKlinger AG / quarterly or semiannual financial statement / ElringKlinger generates growth in sales revenues of 12 percent and earnings growth of 23 percent in the first half of the year
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 10.08.2006 > Consolidated net income after minorities increases 23% > Operating result 21% higher > Operating cash flow increases 58% > Order backlog 16% higher Dettingen/Erms, August 10, 2006 ...
mehr
12.06.2006 – 12:38
Wirtschaft
BASF SE
BASF Completes Acquisition of Engelhard Corporation
Ludwigshafen, Germany (ots/PRNewswire) - - BASF CEO Hambrecht: 'We started the integration process.' BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced the successful completion of its acquisition of Engelhard Corporation (NYSE: EC). "Together with the Engelhard team we have started the integration process in which our customers continue to be the key priority," ...
mehr
23.05.2006 – 17:06
Wirtschaft
Boehringer Ingelheim
New Data Shed Light on the Global Incidence of Constipation
Ingelheim, Germany (ots/PRNewswire) - - Not for Distribution or Publication in the United States New omnibus data from the largest global survey due to be published, conducted on the epidemiology of constipation, were presented today at the Digestive Disease Week congress in Los Angeles. The survey, sponsored by Boehringer Ingelheim, offers new insights into the incidence of constipation and shows that ...
mehr
22.05.2006 – 06:04
Wirtschaft
Boehringer Ingelheim
New Evidence Validates Global Prevalence and Severity of Abdominal Cramping and Pain
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25% of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international gastroenterology congress Digestive Disease Week (DDW) 2006 ...
mehr

Vorherige13141516171819202122Nächste